Search

Displaying results 2001 - 2010 of 2954 in total
  1. Drug

    Choline alfoscerate

    go.drugbank.com/drugs/DB04660
    Investigational

    (From Stedman, 26th ed) It counteracts the effects of urea on enzymes and other macromolecules. [PubChem]

  2. Drug

    Nadolol

    go.drugbank.com/drugs/DB01203
    ApprovedInvestigational

    [A34177] Nadolol was granted FDA approval on 10 December 1979.[L7922]

  3. Drug

    Chymopapain

    go.drugbank.com/drugs/DB06752
    ApprovedWithdrawn

    [A32688] Chymopapain was developed by Chart Medcl and FDA approved on November 10, 1982. It is currently discontinued.[L2487]

  4. Drug

    Eptinezumab

    go.drugbank.com/drugs/DB14040
    ApprovedInvestigational

    [F94,A33105,A33106,A33108] It was approved by the FDA in February 2020 for the preventive treatment of migraine headaches in adults.[L12318]

  5. Drug

    Sulopenem etzadroxil

    go.drugbank.com/drugs/DB16335
    ApprovedInvestigational

    [L51768] Sulopenem etzadroxil was approved by the FDA in October 2024 for the treatment of uncomplicated urinary tract infections.

  6. Drug

    Nitrilotriacetic acid

    go.drugbank.com/drugs/DB03040
    Experimental

    (From Miall's Dictionary of Chemistry, 5th ed.)

  7. Drug

    Betibeglogene autotemcel

    go.drugbank.com/drugs/DB16900
    ApprovedInvestigational

    [A251770,A251785] Betibeglogene autotemcel was approved by the FDA in August 2022 and is the first ex-vivo lentiviral vector gene therapy available in the U.S. for the treatment of people with β-thalassemia

  8. Drug

    Myristic acid

    go.drugbank.com/drugs/DB08231
    Investigational

    Mixtures: Jayjun Real Water Shining Vita Cleansing Foa M, Jayjun Real Water Brightening Black Mask Step 01 Real Water Cleansing Foa M
  9. Drug

    Dinutuximab

    go.drugbank.com/drugs/DB09077
    ApprovedInvestigational

    It is indicated, in combination with granulocyte-macrophage colony-stimulating factor (GM-CSF), interleukin-2 (IL-2), and 13-cis-retinoic acid (RA), for the treatment of pediatric patients with high-risk

  10. Drug

    Belantamab mafodotin

    go.drugbank.com/drugs/DB15719
    ApprovedInvestigationalWithdrawn

    [L53673] Later that year in October of 2025, belantamab was granded full approval by the FDA for the a similar indication to the Health Canada one. [L54331] … [A216756] Belantamab mafodotin was granted FDA accelerated approval on 5 August 2020 for the treatment of multiple myeloma;[L15326] however, its manufacturer began the process for withdrawal of the